Fa'amatalaga atili ― Samoan

Squamous cell carcinoma (SCC) o le lona lua sili ona taatele o le kanesa o le pa'u i le Iunaite Setete, ina ua uma le basal cell carcinoma. E masani ona amata mai i manu'a a'o le'i kanesa e ta'ua o le actinic keratosis , ma e mafai ona sosolo atu i isi vaega o le tino. O le mafuaʻaga autu o le faʻaalia i le ultraviolet (UV) radiation mai le la, lea e faʻaputuina i le taimi. Togakifiga e masani ona aofia ai le tipi tipitipi, aemaise mo le SCC ile ulu ma le ua. O togafitiga fa'avevela ose filifiliga mo gasegase matutua po'o i latou e le mafai ona faia se taotoga. Immunosuppression fa'ateleina le lamatiaga o le SCC. E ui lava e seasea, SCC e mafai ona sosolo, aemaise lava i tagata mamaʻi e vaivai le puipuiga. O siaki masani ma le puipuiga o le la e taua mo i latou e maua i le SCC.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.

Cutaneous squamous cell carcinoma (CSCC) o le kanesa lona lua e sili ona masani i tagata, ma ua fa'atupula'i ona fa'aauau le tele. E ui o le CSCC e masani ona fa'aalia se lesona faʻapitoa i le paʻu, e mafai ona sosolo i isi vaega o le tino. Ua iloa e saienitisi ni auala fa'atatau e aofia ai i le atina'eina o le CSCC, e o'o atu ai i togafitiga fou. O le maualuga o le numera o suiga ma le fa'ateleina o aafiaga i tagata mama'i fa'ama'i na mafua ai le atina'eina o le immunotherapy. O lenei iloiloga o lo'o va'ava'i i a'a o le CSCC ma togafitiga aupito lata mai e fa'atatau i mole mole ma le immune checkpoint inhibitors (immune checkpoint inhibitors).
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors